J&J Cancer Treatment Sales Surge Amid Ambitious Growth Projections

Johnson & Johnson (JNJ) has established itself as a leading player in the oncology market, thanks to its diverse portfolio of treatments for hematologic malignancies and solid tumors. The company's Darzalex is widely regarded as the standard of care for multiple myeloma and remains J&J's top-selling medicine.

Oncology accounts for nearly 29% of J&J's total revenues, with sales reaching $7.4 billion in the second quarter of 2026 on an operational basis. The company attributes this growth to continued momentum from Darzalex and prostate cancer treatment Erleada, despite weaker demand for Imbruvica.

J&J is confident that it can meet its goal of becoming the #1 oncology company by 2030, with sales projected to exceed $50 billion. The company cites strong growth in its marketed cancer drugs and new launches like Rybrevant and Inlexzo as evidence of its progress.